Suppliers / Chongqing Southwest No.2 Pharmaceutical Factory
Chongqing Southwest No.2 Pharmaceutical Factory
China Updated 9 July 2026
Chongqing Southwest No.2 Pharmaceutical Factory is an API manufacturer based in China. It holds one active US drug master file and one valid CEP across a filed portfolio of 2 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 31 May 2024 as VAI.
2
registered plants
1 with an FDA FEI number
0
filings
across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 31 May 2024 VAI US FDA
- 28 April 2017 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| China, China | 3008857790 |
| Chongqing, China | Not on file |
What they file, and where
| Molecule | Regulators | Docs |
| Benzocaine | US FDA | 1 |
| Procaine | EDQM | 1 |
Also appears on these molecule pages
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | None | 1 |
Comparing suppliers?
Choose your molecules and target markets. Chongqing Southwest No.2 Pharmaceutical Factory comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 31 May 2024.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates